Filtered By:
Condition: Thrombosis
Cancer: Cancer

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 663 results found since Jan 2013.

Cancer, other comorbidity, and risk of venous thromboembolism after stroke: a population-based cohort study
The impact of cancer and other comorbidity on the risk of venous thromboembolism (VTE) after stroke is poorly understood.
Source: Thrombosis Research - September 28, 2016 Category: Hematology Authors: Priscila Corraini, Anne Gulbech Ording, Victor W. Henderson, Szimonetta Sz épligeti, Erzsébet Horváth-Puhó, Henrik Toft Sørensen Tags: Original Article Source Type: research

Venous Thrombotic Recurrence After Cerebral Venous Thrombosis Clinical Sciences
Conclusions—In our cohort of CVT patients followed on average for>6 years, subjects with a previous venous thrombotic event, cancer/malignant hemopathies, and unknown CVT causes were found to be at higher risk of recurrence.
Source: Stroke - January 22, 2017 Category: Neurology Authors: Paola Palazzo, Pierre Agius, Pierre Ingrand, Jonathan Ciron, Matthias Lamy, Aline Berthomet, Paul Cantagrel, Jean-Philippe Neau Tags: Cerebrovascular Disease/Stroke Original Contributions Source Type: research

Respond, Intervene and Escalate: Acute Stroke Events in the Post Anesthesia Care Unit
In the post-anesthesia care unit (PACU) setting there can be challenges in differentiating between anesthesia-related versus thrombolytic neurologic deficits. The ability to accurately assess, differentiate and escalate care is imperative to improve outcomes. The occurrence of acute stroke events in the peri-operative setting at a comprehensive cancer center emphasized the need for an evidence-based and comprehensive approach to assessment, communication and documentation of risk factors for thrombotic complications.
Source: Journal of PeriAnesthesia Nursing - July 31, 2019 Category: Nursing Authors: Lisa Jiang, Heather Douglas, Miguel Laxa, Leena Mathew, Sharon Sarmiento, Kimberly Vanderhorst, Elizabeth Vogler Tags: ASPAN National Conference Abstract Source Type: research

Hand knob stroke from cancer-associated thromboembolism.
PMID: 31636165 [PubMed - in process]
Source: cmaj - October 20, 2019 Category: General Medicine Authors: Tomoda Y, Tanaka M, Tanaka K Tags: CMAJ Source Type: research

Concomitant AngioVac thrombectomy and patent foramen ovale closure in a patient with a large right atrial thrombus and recent paradoxical embolic stroke.
Abstract A 59-year-old male with a history of gallbladder adenocarcinoma receiving chemotherapy and on therapeutic anticoagulation for portal vein thrombosis presented to the emergency department via ambulance after being found unresponsive and in cardiac arrest. Initial workup upon return of spontaneous circulation revealed a large right atrial mass, patent foramen ovale (PFO), and bilateral acute cortical infarctions. This constellation of findings were concerning for PFO-related paradoxical embolic strokes. Given the risk of recurrent paradoxical embolic events and the absolute contraindication to thrombolysis ...
Source: Diagnostic and Interventional Radiology : The Turkish Society of Radiology - February 18, 2021 Category: Radiology Authors: Callese TE, Yang EH, Levi D, Srinivasa RN, Moriarty JM Tags: Diagn Interv Radiol Source Type: research

Deep learning-based classification of DSA image sequences of patients with acute ischemic stroke
CONCLUSION: Our deep learning-based approach to thrombus identification in DSA sequences yielded high accuracy on our single-center test data set. External validation is now required to investigate the generalizability of our method. As demonstrated, using this new approach may help reduce the incident risk of overlooking thrombi during thrombectomy in the future.PMID:35604489 | DOI:10.1007/s11548-022-02654-8
Source: Cancer Control - May 23, 2022 Category: Cancer & Oncology Authors: Benjamin J Mittmann Michael Braun Frank Runck Bernd Schmitz Thuy N Tran Amine Yamlahi Lena Maier-Hein Alfred M Franz Source Type: research

Cryptotanshinone Attenuates Oxygen-Glucose Deprivation/ Recovery-Induced Injury in an in vitro Model of Neurovascular Unit
Conclusions Despite the above limitations, we indicate that the protective mechanism of CTs against OGD/R damage might exert via inhibiting neuron apoptosis and attenuating BBB disruption. Furthermore, we also clarified that CTs inhibited neuronal apoptosis possibly by blocking the activation of MAPK signaling pathways, and CTs alleviating BBB disruption may associated with the regulation of TJPs and MMP-9 in our experiment. Accordingly, CTs will represent a novel and potent candidate for the treatment of CIRI in the future. Ethics Statement This study was carried out in accordance with the recommendations of China�...
Source: Frontiers in Neurology - April 17, 2019 Category: Neurology Source Type: research

Associations of Anemia With Outcomes in Patients With Spontaneous Intracerebral Hemorrhage: A Meta-Analysis
Conclusions: Anemia on admission was associated with higher mortality and an increased risk of poor outcome in patients with ICH. However, the results were limited by the high heterogeneity of included studies. Prospective, multi-center or population-based, large sample cohort studies are needed in the future. Introduction Intracerebral hemorrhage (ICH) is the second most common cause of stroke and a highly lethal disease (1), which still lacks effective therapeutic interventions (2, 3). Although age, baseline ICH volume and neurological status on admission are well-known predictors of outcome of ICH (4), none of t...
Source: Frontiers in Neurology - April 24, 2019 Category: Neurology Source Type: research

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Platelet Indices and Risk of Death and Cardiovascular Events: Results from a Large Population-Based Cohort Study.
In conclusion, elevated platelet count is associated with higher mortality and risk of CV events, regardless of previous MI and stroke. Platelet count may thus be a useful marker for further stratification of CV risk, and especially of death. PMID: 31430798 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 19, 2019 Category: Hematology Authors: Patti G, Di Martino G, Ricci F, Renda G, Gallina S, Hamrefors V, Melander O, Sutton R, Engström G, De Caterina R, Fedorowski A Tags: Thromb Haemost Source Type: research

Current and future perspectives on the treatment of cerebral ischemia.
Authors: Christophe BR, Mehta SH, Garton AL, Sisti J, Connolly ES Abstract INTRODUCTION: After heart disease and combined forms of cancer, stroke is the leading cause of death in the United States. Currently, tissue-plasminogen activator (tPA) thrombolysis is the only thrombolytic therapy that has been shown to improve patient outcome. Presently, the only antithrombotic drug treatment that has proven effective at improving acute ischemic stroke patient outcome is aspirin administration. Despite these studies, no clinical trials have yet demonstrated a reliably effective pharmacological treatment. Areas covered: We ...
Source: Expert Opinion on Pharmacotherapy - April 11, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study
Conclusions:The risks of cardiovascular disease and cancer were not elevated among postmenopausal women using vaginal estrogens, providing reassurance about the safety of treatment. Objective: To determine the association between use of vaginal estrogen and risk of a global index event (GIE), defined as time to first occurrence of coronary heart disease (CHD), invasive breast cancer, stroke, pulmonary embolism, hip fracture, colorectal cancer, endometrial cancer, or death from any cause. Methods: For this prospective observational cohort study, we used data from participants of the Women's Health Initiative Observat...
Source: Menopause - December 22, 2017 Category: OBGYN Tags: Original Articles Source Type: research

Cancer and Cerebrovascular Disease
AbstractPurpose of ReviewTo review the latest information about the interactions between cancer and cerebrovascular disease.Recent FindingsAdditional data support the finding that both ischemic and hemorrhagic stroke are important complications of cancer or its treatment. Reperfusion therapy is being given successfully to patients with stroke complicating cancer.SummaryHemorrhagic stroke may occur with metastatic disease to the brain, coagulopathies from cancer, in particular leukemia, or as complications of chemotherapy. Ischemic stroke also may be a complication of metastatic disease with local invasion of vessels, a pro...
Source: Current Neurology and Neuroscience Reports - August 22, 2019 Category: Neuroscience Source Type: research